Related Experiment Video

Updated: May 27, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Therapies using anti-angiogenic peptide mimetics of thrombospondin-1

Jack Henkin1, Olga V Volpert

  • 1Chemistry of Life Processes Institute, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, USA.

Expert Opinion on Therapeutic Targets
|December 6, 2011
PubMed
Abstract

Insights

Thrombospondin-1 (TSP1) is a key angiogenesis inhibitor, offering potential drug candidates for cancer and other diseases. TSP1-derived peptides show promise in treating angiogenesis-dependent conditions, including neovascular ocular diseases and ovarian cancer.

Area of Science:

  • Molecular Biology
  • Drug Discovery
  • Oncology

Background:

  • Thrombospondin-1 (TSP1) is a critical endogenous inhibitor of angiogenesis.
  • Its mechanisms and functions are well-established, leading to novel therapeutic strategies.
  • TSP1 plays a role in both cancerous and non-cancerous pathological conditions.

Purpose of the Study:

  • To review the functions and molecular mechanisms of TSP1.
  • To explore the therapeutic potential of TSP1-derived peptides.
  • To summarize TSP1's role in angiogenesis-driven diseases.

Main Methods:

  • Literature review of TSP1 functions, regulation, and signaling.
  • Analysis of TSP1's role in endothelial and non-endothelial cells.
  • Identification and optimization of bioactive peptides from TSP1 domains binding CD47 and CD36.
  • Overview of preclinical and clinical efficacy of TSP1-derived peptides.

Main Results:

  • TSP1 inhibits angiogenesis through interactions with cell surface receptors like CD47 and CD36.
  • Short bioactive peptides derived from TSP1 domains retain anti-angiogenic properties.
  • These peptides have demonstrated efficacy in preclinical and clinical models of angiogenesis-dependent diseases.

Conclusions:

  • TSP1-derived peptides and mimetics represent a promising therapeutic class for angiogenesis-driven diseases.
  • They offer potential solutions for unmet medical needs in conditions like neovascular ocular disease and ovarian cancer.

More Related Videos

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits07:34

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells04:00

A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells

Published on: September 7, 2011

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.